Robbie McLaren

  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom
Profile Experience

Robbie McLaren’s practice primarily includes cross-border mergers and acquisitions, joint ventures, and emerging companies. Mr. McLaren represents clients who primarily operate in the life sciences, healthcare, and technology industries. Mr. McLaren is Global Vice Chair of the firm’s Healthcare & Life Sciences Industry Group and former Co-Chair of the London Corporate Department.

Mr. McLaren's experience includes advising:
Life Sciences and Healthcare
  • Eleusis, one of the leading psychedelics to medicine science companies, on its:
    • US$446 million merger with Silver Spike Acquisition Corp.
    • Acquisition of Kalypso TC, a provider of ketamine infusion therapies used to treat mental and physical conditions, such as major depressive disorder
  • Abcam, a global leader in the supply of life science research tools on its US$340 million acquisition of BioVision
  • BC Partners on the acquisition of a majority interest in the complex generic medicines business of Synthon International, a Netherlands-based multinational pharmaceutical company
  • Atnahs Pharma on its acquisition of assets related to five hypertension medicine brands from AstraZeneca
  • Acino on its acquisition of various pharmaceutical products and related assets in the NEMEA region from Takeda
  • Apotex on the sale of two pharmaceutical products to Intas which are aimed at stimulating white blood cells during chemotherapy
  • 8VC on the sale of their shares in Digital Surgery to Medtronic
  • Baxter International Inc., in connection with its US$625 million acquisition of Claris Injectables Limited, an India-based manufacturer of sterile injectables
  • Sienna Biopharmaceuticals in connection with its acquisition of Creabilis plc, a privately held specialty pharmaceutical company
  • An Asian investor on their investment into Aerogen, an acute aerosol drug delivery business
  • The shareholders of Pharmathen SA, a Greek pharmaceuticals company, on their sale of a controlling interest in Pharmathen to BC Partners
  • Zogenix on its acquisition of Brabant Pharma, a UK-based pharmaceutical company
  • Novo A/S in:
    • Its £230 million disposal of Archimedes
    • Its US$800 million acquisition of Xellia
    • Its £400 million acquisition of BBI
    • Connection with the initial public offering of ADS on Nasdaq of Freeline Therapeutics
  • Watson Pharmaceuticals / Actavis / Allergan on its:
    • €4.25 billion acquisition of the Actavis Group, making Watson the third largest global generics company
    • Divestment of part of its Western European generics sale and marketing business to Aurobindo
    • US$40.5 billion sale of its global generics pharmaceuticals business to Teva
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its:
    • US$703 million acquisition by CVC Capital Partners of women’s healthcare assets from Teva Pharmaceutical Industries Ltd
    • Acquisition of certain pharmaceutical products from Janssen
Technology, Media, and Telecoms
  • Darktrace plc in connection with its £1.7 billion initial public offering and listing on the London Stock Exchange
  • The underwriters in connection with the £7.59 billion IPO of Deliveroo Holdings plc, listed on the London Stock Exchange
  • Vertical Aerospace on its US$2.2 billion business combination with Broadstone Acquisition Corp., a special purpose acquisition company
  • Centricus Acquisition Corp, a special purpose acquisition company, on its US$1 billion business combination with Arqit, a London-based developer of a quantum encryption platform
  • Canva, an Australia-based online graphic design and publishing company, on its acquisition of Kiln Enterprises, a data visualization company
  • Impact Holdings, Inc. on its acquisition of Trackonomics, a data management and digital marketing company
  • Mimecast on the acquisition of Simply Migrate, a London-based provider of archive data migration technology
  • Sony Pictures Entertainment and its subsidiary, Columbia Pictures Corporation, on the acquisition of Silvergate Media, a developer of children’s brands for broadcasters, streaming platforms, and retail partners (including the Octonauts, Peter Rabbit, and Hilda animated series)
  • Selina on their equity financings, including its US$125m Series C financing
  • Hyundai on its investment into AppyParking, a company providing parking apps and services for drivers
  • An Asian investor on their equity investment in:
    • Sound Cloud, a Germany-based company engaged in providing online audio platform services
    • Claroty, a cybersecurity software company
    • Common Sense Robotics
  • Telenor on its €2.8 billion sale of its assets in Central and Eastern Europe (CEE) to PPF Group
  • Kite Tech, a UK-based mobile e-commerce platform specializing in personalized print on its sale to Canon Europa
  • Netflix Inc. on the acquisition of Millarworld, a comic book company founded by Mark Millar
  • Andreessen Horowitz on its minority investment in Improbable World Limited, a UK-based software developer focused on virtual and simulated worlds
  • Intapp on their acquisition of Rekoop
  • The Carlyle Group on its US$400 million investment in Ion Trading and its US$700 million acquisition of Dealogic
  • Calysta on its acquisition of BioProtein A/S
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.